Liminal BioSciences Pulls Plug On Its Lead Development Program
Liminal BioSciences Inc (NASDAQ:LMNL) will discontinue the development of fezagepras based on results from the Phase 1a single ascending dose (SAD)…
ClearPoint Neuro Congratulates Partner PTC Therapeutics On Being Granted Marketing Authorization By The European Commission For Upstaza – First Disease-Modifying Treatment For AADC Deficiency
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted
With All Eyes On Lecanemab Read Out In Alzheimer’s, Uncertainty Overshadows Biogen’s Q2 Beat
Yesterday, Biogen Inc (NASDAQ:BIIB) reported Q2 earnings. Needham writes that while operational performance looked good, uncertainty looms over the company’s growth potential. Lecanemab Phase…
‘Potential fabrication in research images threatens key theory of Alzheimer’s disease’ -Science.org Report
https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease
HC Wainwright Starts Coverage On This ‘Best-In-Class Agent For Inflammatory Disorders
HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class…
House Now Voting On Legislation That Would Enshrine Federal Protection Of Access To Contraceptives Without Government Restrictions Into Law
https://twitter.com/CraigCaplan/status/1550143822281297920
Molecular Partners Announces Publication In Nature Biotechnology Detailing Design And Mechanism Of Ensovibep DARPin Antiviral For SARS-CoV-2
Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of key
What’s Happening With Addex Therapeutics Shares Today
Addex Therapeutics Ltd (NASDAQ:ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share…